Prostate Cancer - Results from #80

Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial. December 11, 2024

ERG and PTEN Role on Active Surveillance for Low-Risk Prostate Cancer in the Multiparametric MRI Era. December 11, 2024

Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer. December 11, 2024

A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis. December 11, 2024

Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer. December 11, 2024

Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer. December 11, 2024

Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet®) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer. December 11, 2024

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. December 10, 2024

Ultra-high gradient performance 3-Tesla MRI for super-fast and high-quality prostate imaging: initial experience. December 10, 2024

Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison. December 10, 2024

Survival Outcomes and Recurrence Patterns Following Focal High-intensity Focused Ultrasound Treatment for Localized Prostate Cancer: Insights on Patient Selection and Lessons Learned. December 10, 2024

The Added Value of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography to Magnetic Resonance Imaging for Local Staging of Prostate Cancer in Patients Undergoing Radical Prostatectomy. December 10, 2024

Spatial Transcriptomic Profiling to Characterize the Nature of Peripheral- Versus Transition-zone Prostate Cancer. December 10, 2024

Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery. December 10, 2024

Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study. December 9, 2024

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy. December 9, 2024

Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data. December 9, 2024

Experience of urologists, oncologists and nurse practitioners with mainstream genetic testing in metastatic prostate cancer. December 9, 2024

Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers. December 9, 2024

Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer. December 9, 2024

Page 5 of 1448